Several other brokerages have also commented on MTFB. Northland Securities restated a buy rating on shares of Motif Bio in a research note on Thursday, October 5th. FinnCap reiterated a buy rating and issued a GBX 100 ($1.36) target price on shares of Motif Bio in a research note on Wednesday, October 4th. Finally, Beaufort Securities reiterated a speculative buy rating and issued a GBX 110 ($1.49) target price on shares of Motif Bio in a research note on Thursday, November 16th.
Shares of Motif Bio (LON:MTFB) traded up GBX 0.35 ($0.00) on Wednesday, hitting GBX 41.10 ($0.56). 608,849 shares of the stock traded hands, compared to its average volume of 886,306. Motif Bio has a 52 week low of GBX 22.50 ($0.31) and a 52 week high of GBX 51.75 ($0.70). The firm has a market cap of $108.06 and a price-to-earnings ratio of -152.22.
TRADEMARK VIOLATION WARNING: “Peel Hunt Reaffirms “Buy” Rating for Motif Bio (MTFB)” was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thestockobserver.com/2018/01/14/peel-hunt-reaffirms-buy-rating-for-motif-bio-mtfb.html.
Motif Bio Company Profile
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.